Session Information
Date: Sunday, November 8, 2015
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: The Psoriatic Arthritis Impact of
Disease (PsAID) PRO measure was developed for clinical trials (9 item) and
routine care (12 item) in Psoriatic arthritis (PsA) in multiple languages
including Turkish. PsAID12 items (pain, fatigue, skin, work/leisure, function,
discomfort, sleep, coping, anxiety, embarrassment, social life, depression) are
11 point numerical rating scales from 0 none/very well to 10 extreme/very
poorly. PSAID12≤4 is considered patient acceptable symptom state. The performance
of PsAID12 has not been reported to date in an independent PsA cohort.
Methods: Hacettepe University Rheumatology
Biological database is a single center registry of 2700 patients with
inflammatory arthritis (including PsA) on biologicals followed longitudinally.
We collect demographics, clinical characteristics, 28 tender/swollen joint
counts, CRP, health assessment questionnaire (HAQ), dermatology life quality
index (DLQI), Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath
Ankylosing Spondylitis Functional Index (BASFI), 100mm visual analog scales
(VAS) for patient global
assessment (PtGA), fatigue and pain. At the baseline visit we calculated: Spearman
correlation coefficient of PSAID12 with measures of disease activity, function,
quality of life and symptoms; and kappa statistic for agreement of PSAID12>4
with DAS28>2.6 and BASDAI>4.
Results: There were 163 PsA patients
66.3% female, 27.6% axial disease, mean(SD) ( yrs) age 44.8(11.8), duration of PsA
10.3(7.3) and psoriasis 16.8(8.7). Mean(SD) scores were PsAID12 4.1(2.5), DAS28
3.04(1.41) and BASDAI 3.9(2.2). A PsAID12 score >4 (52.8% patients) was
associated with female (59% vs 40%, p=0.020), BMI>30 (66.6% vs 43.5%,
p=0.005), diabetes (80.0% vs 50.0%, p=0.027), hypertension (70.0% vs 48.8%,
p=0.036), no axial disease (57.6% vs 40.0%, p=0.044). Correlations between
measures are presented in Table. PsAID12>4 agreement with DAS28>2.6 was
kappa=0.53 (95%CI 0.38-0.67) and with BASDAI>4 was kappa=0.60 (95%CI
0.48-0.73).
Conclusion: In this group of PsA
patients, PSAID12 had moderate-high correlation with PROs reflecting PsA
symptoms, functional impairment and quality of life, but not with CRP.
PSAID12had moderate-high agreement with PsA disease activity as measured by
DAS28 and BASDAI. Our data support convergent construct validity of PsAID12 in
an independent PsA cohort. Additional evaluations of longitudinal construct
validity and responsiveness are needed.
Table : Correlation coefficients of
PsAID12 with disease activity and PsA outcome measures
|
|
PSAID12 |
DAS28* |
BASDAI |
Pain |
Fatigue |
BASFI |
HAQ-DI |
DLQI |
PtGA |
CRP (mg/dL) |
|
PSAID12 |
1.00 |
0.55 |
0.72 |
0.54 |
0.54 |
0.67 |
0.69 |
0.59 |
0.64 |
0.22 |
|
DAS28 |
0.55 |
1.00 |
0.59 |
0.57 |
0.57 |
0.47 |
0.47 |
0.28 |
0.67 |
0.51 |
|
BASDAI |
0.72 |
0.59 |
1.00 |
0.73 |
0.68 |
0.76 |
0.64 |
0.33 |
0.75 |
0.22 |
|
Pain |
0.54 |
0.57 |
0.73 |
1.00 |
0.67 |
0.53 |
0.52 |
0.36 |
0.83 |
0.24 |
|
Fatigue |
0.53 |
0.57 |
0.68 |
0.67 |
1.00 |
0.51 |
0.49 |
0.29 |
0.75 |
0.19 |
|
BASFI |
0.67 |
0.47 |
0.76 |
0.53 |
0.51 |
1.00 |
0.75 |
0.39 |
0.55 |
0.25 |
|
HAQ-DI |
0.69 |
0.47 |
0.64 |
0.52 |
0.49 |
0.75 |
1.00 |
0.45 |
0.49 |
0.22 |
|
DLQI |
0.59 |
0.28 |
0.33 |
0.36 |
0.29 |
0.39 |
0.45 |
1.00 |
0.38 |
0.02 |
|
PtGA |
0.64 |
0.67 |
0.75 |
0.83 |
0.75 |
0.55 |
0.49 |
0.38 |
1.00 |
0.23 |
|
CRP (mg/dL) |
0.22 |
0.51 |
0.22 |
0.24 |
0.19 |
0.25 |
0.22 |
0.02 |
0.23 |
1.00 |
|
*DAS-28 data was available for 130 patients. |
||||||||||
To cite this abstract in AMA style:
Kalyoncu U, Kilic L, Erden A, Karadag O, Apras Bilgen S, Kiraz S, Ertenli I, Bingham C, Orbai AM. Convergent Construct Validity of PsAID12 in a Psoriatic Arthritis Cohort at Baseline [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/convergent-construct-validity-of-psaid12-in-a-psoriatic-arthritis-cohort-at-baseline/. Accessed .« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/convergent-construct-validity-of-psaid12-in-a-psoriatic-arthritis-cohort-at-baseline/